Medical College of Wisconsin
CTSIResearch InformaticsREDCap

A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. Biol Blood Marrow Transplant 2020 Dec;26(12):e305-e308

Date

09/14/2020

Pubmed ID

32920205

Pubmed Central ID

PMC7735536

DOI

10.1016/j.bbmt.2020.08.029

Scopus ID

2-s2.0-85092101705 (requires institutional sign-in at Scopus site)   8 Citations

Abstract

Effective immunosuppressive regimens to prevent the development of graft-versus-host disease (GVHD) are essential to the success of allogeneic hematopoietic cell transplantation (HCT). After revolutionizing haploidentical transplantation, post-transplantation cyclophosphamide (PTCy) is now being evaluated for HCT performed from related and unrelated donors. In this setting, 2 recent randomized studies have demonstrated lower rates of GVHD and superior GVHD-free, relapse-free survival with PTCy compared with conventional GVHD prophylaxis. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is currently conducting a large, randomized phase III, multicenter trial (BMT CTN 1703) comparing PTCy/tacrolimus/mycophenolate mofetil to tacrolimus/methotrexate as GVHD prophylaxis regimens in reduced-intensity allogeneic HCT. Here we review the ongoing study, highlight its importance to the field, and explore the possible implications of its results on clinical practice.

Author List

DeFilipp Z, Burns LJ, Jaglowski SM, Leppin AL, Pavletic S, Waldman B, Weisdorf DJ, Wood WA, Khera N

Author

Samantha M. Jaglowski BS, MD, MPH, MBA Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Bone Marrow
Cyclophosphamide
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Multicenter Studies as Topic
Mycophenolic Acid
Randomized Controlled Trials as Topic
Transplantation Conditioning
Unrelated Donors